Dopexamine hydrochloride, a synthetic dopamine analog with predominantly beta and delta agonist properties, has been shown to improve cardiac performance and renal function in adults with heart failure. This study was designed to investigate the haemodynamic and renal effects of dopexamine in children after cardiac surgery.
Dopexamine hydrochloride is a new synthetic catecholamine combining β1, β2 and δ agonist properties. In adults with chronic heart failure or after cardiac surgery, dopexamine improves cardiac index and stroke volume while inducing systemic vasodilation 1-4 . In addition, the drug also improves renal blood flow, glomerular filtration rate and sodium excretion by a selective renal action 5, 6 . Such effects could be of benefit to treat low cardiac output in children. The aim of this study was to assess the haemodynamic and renal effects of a continuous infusion of dopexamine in children after open-heart surgery.
PATIENTS AND METHODS
The study protocol was approved by the Ethics Committee of the Paediatrics Department and written consent was obtained from the legal representative of the child. Seven children, five girls and two boys aged 6 to 15 years were selected because a need for postoperative vasodilator therapy was anticipated following open-heart surgery. Their preoperative clinical characteristics and plasma creatinine clearance are given in Table 1 (digoxin and diuretics) were stopped 12 hours before the beginning of surgery which was performed under cardiopulmonary bypass, deep hypothermia (18 to 24°C) and moderate haemodilution (haematocrit level: 20 to 30%). Cold chemical cardioplegia (St Thomas composition) was used to produce asystole. When cardiopulmonary bypass was discontinued, blood was infused until the pulmonary wedge pressure reached 10 to 14 mmHg, and a single dose of frusemide (1 mg/kg) was given.
Each patient was studied in the intensive care unit, three to four hours after the end of anaesthesia when the clinical condition was stable. Body temperature was normal. Blood losses through the chest tubes were regularly replaced with normal saline infusion to maintain constant right heart filling pressure. None of the patients needed pacing to maintain cardiac rhythm. They were all ventilated with a volumecontrolled ventilator to maintain arterial carbon dioxide tension between 4.5 and 5.5 kPa and sedated with a continuous infusion of midazolam (0.1 mg.kg -1 .h -1 ) and nalbuphin (0.1 mg.kg -1 .h -1 ). A glucose electrolyte solution containing 2 mmol.kg -1 .24h of both NaCl and KCl was infused at a rate of 750 ml.m -2 .24h -1 . Two sets of haemodynamic measurements 90 minutes apart were made without dopexamine infusion to ascertain a stable baseline. The second value served as a control and dopexamine was then infused at 2 and 6 µg.kg. -1 .min -1 for 90 minutes each, the sequence being randomly alternated. These two doses of dopexamine were chosen as they were in the range that has been studied in adults.
Glomerular filtration rate (GFR) and effective renal plasma flow were determined by the clearances of inulin (Laevosan AG, Zürich, Switzerland) and para-aminohippurate (PAH) (BAG, Hessen). A priming dose of PAH (8 mg/kg) and inulin (50 mg/kg) was followed by a continuous infusion in order to achieve a plasma concentration of 20 mg/l for PAH and 200 mg/l for inulin. After an equilibration period of 90 minutes, nine 30-minute urine collections (three during each treatment period) were performed through an intravesical Foley catheter. Blood samples were obtained at the beginning and end of each collection period. PAH and inulin were analysed by colorimetric techniques 7, 8 .
The clearance of PAH was corrected assuming a PAH extraction of 0.9 9 . Renal blood flow was calculated by dividing the corrected PAH clearance by (1-haematocrit) .
The renal fraction of total cardiac output was calculated by dividing the renal blood flow per m 2 of body surface area by cardiac index. Filtration fraction was calculated by dividing GFR/(RPF x 100). Aldosterone plasma concentrations (Diagnostic Prod. Co., Los Angeles, CA; kit TKAL) and renin activity were measured by RIA. Renal clearances within each period were obtained by averaging the results of three individual values obtained over 30-minute urine collections.
Haemodynamic measurements were performed in the middle of each period. Cardiac output was measured by injecting an ice-cold NaCl 0.9% solution through the proximal port of the pulmonary artery catheter. Patients weighing less than 20 kg received 3.5 ml, those more than 20 kg, 5 ml. Three consecutive measurements were averaged for each period. Simultaneously, heart rate, systemic arterial pressure, central venous pressure, and pulmonary wedge pressure were recorded and vascular resistance calculated using standard formulae. During the study the patients did not receive any other medication.
Statistical analysis
Parametric two-way ANOVA for haemodynamic data and non-parametric Wilcoxon signed ranks tests for renal function data were used to test the effect of dopexamine at both doses versus the control period. Neumann-Keuls and Mann-Whitney comparison procedures were performed between different means, when indicated. A P<0.05 was accepted as significant.
RESULTS
( Table 2. )
Control period
During the control period, mean cardiac index was 3.5 (0.74) l.min -1 .m -2 and renal blood flow 319 (113) ml.min -1 .m -2 , so the fraction of the cardiac output delivered to the kidney was 9 (4)%. GFR 
Effects of dopexamine
Cardiovascular effects ( Table 2 and Figure 1 ) With 2 and 6 µg.kg -1 .min -1 of dopexamine, cardiac index significantly increased from a baseline of 3.5 (0.7) to 3.9 (0.75) and 4.5 (0.8) l.min -1 .m -2 respectively (both P<0.05), while heart rate increased from 107 (17) to 122 (17) and 136 (17) beats/min (P<0.05) and pulmonary wedge pressure decreased from 14 (3) to 11 (4) and 12 (3) mmHg (P<0.05). Increases in cardiac index and heart rate with dopexamine 6 µg.kg -1 .min -1 were also significant when compared with the values obtained at 2 µg.kg -1 .min -1 . Systemic vascular resistance significantly decreased from 24 (7) to 20 (5) mmHg.l -1 .min -1 .m -2 (P<0.05) with dopexamine 6 µg.kg -1 .min -1 compared with control. Dopexamine, whether at 2 or 6 µg.kg -1 .min -1 , had no significant effect on stroke volume index, mean systemic arterial pressure, central venous pressure and pulmonary vascular resistance.
Renal effects (Table 2 and Figure 2)
With dopexamine at 2 and 6 µg.kg -1 .min -1 . renal blood flow increased from 319 (113) to 440 (230) and 410 (138) ml.min -1 .m -2 respectively (both P<0.05). The fraction of the cardiac output delivered to the kidney was unchanged (12 (10) and 10 (4) vs 9 (4)%, n.s.). GFR increased from 115 (32) to 142 (34) and 146 (25) ml.min -1 .1.73m -2 (P<0.05), but the filtration fraction remain unchanged. Fractional sodium excretion was 2.24 (1) 
DISCUSSION
Following open heart surgery in children, infusion of dopexamine produced a dose-related increase in heart rate and cardiac output without a change in stroke volume. A decline in pulmonary wedge pressure and systemic vascular resistance was observed at the highest dose of 6 µg.kg -1 .min -1 . These effects relate to β 1 more than β 2 activation and differ from those previously published in adults, where the main action was a decrease in systemic vascular resistance 1, 4, [10] [11] [12] [13] .
In adults after coronary artery bypass grafting, dopexamine at 1 to 10 µg.kg -1 .min -1 primarily induced a dose-dependent decrease in both pulmonary and systemic vascular resistances and an increase in cardiac index, heart rate and systemic arterial pressure 4 . Following surgical procedures similar to those in this study (aortic and mitral valvuloplasty), dopexamine at 0.5 to 3 µg.kg -1 .min -1 also induced an increase in cardiac index, heart rate and systemic arterial pressure without changes in pulmonary wedge pressure and pulmonary resistance 12 . In our study, the rise in cardiac output paralleled the chronotropic effect. The decrease in pulmonary wedge pressure and systemic arterial resistance were observed only at the highest dose of dopexamine, and thus, seemed to be a secondary effect to the increase 437 
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Anaesthesia and Intensive Care, Vol. 24, No. 4, August 1996 in cardiac output rather than to result from a primary vasodilator effect inducing a reflex tachycardia. Hypovolaemia, as a possible bias, was minimized during the study by carefully replacing the blood losses from the chest tubes. Our measurements did not include an index of ventricular contractile function. Thus, the magnitude of the positive inotropic action of dopexamine, as observed in adults at doses of 1 to 2 µg.kg. -1 .min -1 after cardiac surgery 13 or in congestive heart failure 11 at doses of 4 µg.kg. -1 .min -1 could not be quantitated.
With respect to renal function, dopexamine significantly increased RBF and GFR at both dosages. These effects can be related to the rise in cardiac index as the fraction of cardiac output distributed to the kidneys was unchanged and the filtration fraction within the kidneys remained constant. In a previous study in children, we demonstrated that dopamine at 5 µg.kg. -1 .min -1 increased RBF, GFR and urinary sodium excretion with a concomitant reduction in the filtration fraction 14 . This suggested a more pronounced post-compared with pre-glomerular vasodilatory effect by dopamine leading to an alleviation of the compensatory mechanisms, i.e. a reduced activation of the renin-angiotensin-aldosterone system. An increase of the GFR without any increase in the filtration fraction suggests that dopexamine had no effect on pre-or post-glomerular vascular resistances. Again, this is in contrast with adult studies. Olsen et al, comparing the renal effects of dopamine, dopexamine and dobutamine at equipotent inotropic doses in unanaesthetized human volunteers, found that GFR increased only with dopexamine while the increase in RPF was smaller 438 W. HABRE, M. BEGHETTI ET AL Anaesthesia and Intensive Care, Vol. 24, No. 4, August 1996 with dopexamine compared with dopamine 6 . However, the increased GFR with dopexamine was accompanied by a significant increase in natriuresis and urine output at 2 µg.kg. -1 .min -1 . The natriuretic effect of a drug can be explained either by an increase in sodium filtered load or by a direct tubular effect. Dopexamine has been shown to bind specifically to δA-1 and to δA-2 adrenoreceptors, then to stimulate cAMP formation in the human kidney promoting the diuretic and natriuretic effects 5 . Olsen et al found that dopamine but not dopexamine inhibited sodium reabsorption in the proximal tube and in the more distal nephron segments, thus inducing a significant natriuresis 6 . Our data do not allow us to conclude whether the observed increase in sodium excretion relates to the increased sodium load resulting from increased GFR or to inhibition of tubular sodium reabsorption by dopexamine.
The autoregulation of GFR is critically dependent on the action of the renin-angiotensin system 15 . Many studies suggested that the diuretic response to renal dopamine appears to be dependent on the interaction between the vasodilating-natriuretic effect of dopamine and the vasoconstricting anti-natriuretic effect of the renin-angiotensin-aldosterone system 16, 17 . Furthermore, there is a dopaminergic inhibitory modulation of aldosterone production that is mediated by δ-2 receptors in the adrenal cortex 17 . In this study, we failed to show a significant change in plasma renin activity and plasma aldosterone concentration, despite a tendency to decrease under dopexamine perfusion. Also, the control values of the plasma renin activity were within the normal range for age 18 .
In conclusion, in children after cardiac surgery, a continuous infusion of dopexamine at 2 and 6 µg.kg. -1 .min -1 results in more cardiac effects than direct vascular or selective renal effects. Systemic arterial vasodilation appears only at the highest dose and is not accompanied by renal vascular vasodilation. The increased sodium excretion could result from both the increase in GFR or a direct tubular effect. The benefit of this drug in children after cardiac surgery compared to the combined administration of dopamine and a systemic vasodilator remains to be demonstrated.
